7. What is planned by way of launch and availability?

The launch of the product is already underway in various worldwide markets, which includes all western European areas, registration in Canada and FDA approval for the USA. Availability in the short term will be via the direct supply through Advancis Surgical based in the U.K, where we have a large and capable team managing administration, customer service, logistics and support. Moving forward, applications have been made into the NHSSC, Scottish procurement and Welsh procurement for inclusion of the device. Future supply will be included on the NHSSC to ensure all sites can receive comprehensive delivery and service in a manner they are accustomed to with other product categories. Comprehensive training will be provided directly to clinicians by way of initial interaction and future on-going training if required. Full stock levels are currently accessible via Advancis Surgical with provisions in place for increased demand in the initial term

Posted in: Hemosep